Stock NVAX NOVAVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
3.97 USD +2.06% Intraday chart for Novavax, Inc. -7.24% -17.29%
Apr. 15 Sector Update: Health Care Stocks Gain Monday Afternoon MT
Apr. 15 Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... Our Logo

Business Summary

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Number of employees: 1,543

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Vaccines
100.0 %
1,982 100.0 % 984 100.0 % -50.36%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1,982 100.0 % 984 100.0 % -50.36%

Managers

Managers TitleAgeSince
John Jacobs CEO
 Chief Executive Officer 57 23-01-22
John Trizzino PSD
 President 64 14-03-09
James Kelly DFI
 Director of Finance/CFO 58 21-08-15
Troy Morgan CMP
 Compliance Officer - 21-04-18
Raburn Mallory CTO
 Chief Tech/Sci/R&D Officer - 19-12-31
Seth Toback CTO
 Chief Tech/Sci/R&D Officer - 20-06-30
Gale Smith CTO
 Chief Tech/Sci/R&D Officer - 03-12-31
Filip Dubovsky CTO
 Chief Tech/Sci/R&D Officer 59 20-06-16
Biegie Lee CTO
 Chief Tech/Sci/R&D Officer - 16-12-31
Silvia Taylor IRO
 Public Communications Contact - 20-06-16

Members of the board

Members of the board TitleAgeSince
Richard Rodgers BRD
 Director/Board Member 57 22-10-28
Gregg Alton BRD
 Director/Board Member 58 20-10-31
David Mott BRD
 Director/Board Member 58 20-06-15
James Young CHM
 Chairman 71 10-04-06
Margaret McGlynn BRD
 Director/Board Member 64 20-12-06
Rachel King BRD
 Director/Board Member 64 18-10-31
Richard Douglas BRD
 Director/Board Member 71 10-08-05
John Jacobs CEO
 Chief Executive Officer 57 23-01-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 140,953,466 132,964,447 ( 94.33 %) 1,000,323 ( 0.7097 %) 94.33 %

Shareholders

NameEquities%Valuation
STATE STREET CORPORATION
11.99 %
16,775,875 11.99 % 80 M $
Vanguard Fiduciary Trust Co.
10.40 %
14,560,061 10.40 % 70 M $
Shah Capital Management, Inc.
6.664 %
9,326,176 6.664 % 45 M $
BlackRock Advisors LLC
5.622 %
7,867,972 5.622 % 38 M $
Shah Capital Management, Inc.
5.560 %
7,780,756 5.560 % 37 M $
Morgan Stanley Investment Management, Inc.
5.174 %
7,241,455 5.174 % 35 M $
SK BIOSCIENCE CO.,LTD.
4.644 %
6,500,000 4.644 % 31 M $
Geode Capital Management LLC
1.642 %
2,297,507 1.642 % 11 M $
Rafferty Asset Management LLC
1.152 %
1,611,840 1.152 % 8 M $
Coatue Management LLC
1.086 %
1,519,594 1.086 % 7 M $

Company contact information

Novavax, Inc.

700 Quince Orchard Road

20878, Gaithersburg

+240 268 2000

http://www.novavax.com
address Novavax, Inc.(NVAX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Novavax, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.89 USD
Average target price
15.4 USD
Spread / Average Target
+295.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NOVAVAX, INC. Stock Novavax, Inc.
-18.96% 544M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.78% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. Company Novavax, Inc.